U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

  • March 2019: Olanzapine has been removed by NICE from recommendation 1.6.4 because the clinical need can now be met by a licensed product. The footnote to this recommendation stated that haloperidol and olanzapine do not have UK marketing authorisation for delirium treatment. However, haloperidol does now have marketing authorisation. Therefore, the footnote has been removed because it no longer applies to haloperidol. Recommendation 1.5.1 has been amended because a delirium diagnosis is now confirmed using DSM-V.

March 2019: Olanzapine has been removed by NICE from recommendation 1.6.4 because the clinical need can now be met by a licensed product. The footnote to this recommendation stated that haloperidol and olanzapine do not have UK marketing authorisation for delirium treatment. However, haloperidol does now have marketing authorisation. Therefore, the footnote has been removed because it no longer applies to haloperidol. Recommendation 1.5.1 has been amended because a delirium diagnosis is now confirmed using DSM-V.

Cover of Delirium

Delirium

Diagnosis, Prevention and Management

NICE Clinical Guidelines, No. 103

.

Excerpt

This guideline covers adult patients (18 years and older) in a hospital setting and adults (18 and older) in long-term residential care. The guideline addresses: modifiable risk factors (‘clinical factors’) to identify people at risk of developing delirium; diagnosis of delirium in acute, critical and long-term care; as well as pharmacological and non-pharmacological interventions for a) reducing the incidence of delirium and its consequences, and b) to reduce the severity, duration and consequences of delirium in people who develop the condition.

Contents

Copyright © 2010, National Clinical Guideline Centre - Acute and Chronic Conditions.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright Designs and Patents Act, 1988.

Bookshelf ID: NBK65558PMID: 22319805

Views

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...